MDL | MFCD32858282 |
---|---|
Molecular Weight | 431.49 |
Molecular Formula | C23H25N7O2 |
SMILES | O=C1N(C)C(NC(C)C)=NC=C1C2=NC(C)=C(OC3=CC(C4=CN(C)N=C4)=NC=C3)C=C2 |
IC50: <0.01 μM (c-FMS/CSF-IR), 0.1-1 μM (c-Kit) [1]
Vimseltinib is a c-FMS (CSF-IR) and c-Kit dual inhibitor with anti-cancer and anti-proliferative activities [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT04242238 | Memorial Sloan Kettering Cancer Center |
Sarcoma|Advanced Sarcoma|High Grade Sarcoma|Leiomyosarcoma|Undifferentiated Pleomorphic Sarcoma|Myxofibrosarcoma|Dedifferentiated Liposarcoma
|
January 22, 2020 | Phase 1 |
NCT03069469 | Deciphera Pharmaceuticals LLC |
Advanced Malignant Neoplasm|Pigmented Villonodular Synovitis|Giant Cell Tumor of Tendon Sheath|Tenosynovial Giant Cell Tumor|Tenosynovial Giant Cell Tumor, Diffuse
|
February 16, 2017 | Phase 1|Phase 2 |
NCT05059262 | Deciphera Pharmaceuticals LLC |
Tenosynovial Giant Cell Tumor|Pigmented Villonodular Synovitis|Giant Cell Tumor of Tendon Sheath|Tenosynovial Giant Cell Tumor, Diffuse|Tenosynovial Giant Cell Tumor, Localized
|
October 14, 2021 | Phase 3 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 50 mg/mL ( 115.88 mM ; ultrasonic and warming and heat to 60°C)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.3176 mL | 11.5878 mL | 23.1755 mL |
5 mM | 0.4635 mL | 2.3176 mL | 4.6351 mL |
10 mM | 0.2318 mL | 1.1588 mL | 2.3176 mL |